Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#3525 Prognostic factors for progression-free survival (PFS) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated lanreotide autogel/depot (LAN) in metastatic somatostatin receptor (SSTR)-positive typical and atypical (TC and AC) BP NETs.

Conference:

Presenting Author: Baudin E

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, prognostic factor, spinet, typical/atypical carcinoid,

#3518 Effect of lanreotide autogel/depot (LAN) on tumor growth rate (TGR) in patients with metastatic bronchopulmonary neuroendocrine tumors (BP-NETs): Exploratory data from the phase 3 SPINET study

Introduction: SPINET (NCT02683941) evaluated LAN in metastatic somatostatin receptor (SSTR)-positive typical and atypical carcinoid (TC and AC) BP-NETs.

Conference:

Presenting Author: Capdevila J

Authors: Baudin E, Hörsch D, Singh S, Caplin M, Ferone D,

Keywords: bronchopulmonary neuroendocrine tumor, lanreotide autogel/depot, spinet, tumor growth rate, typical/atypical carcinoid,

#3333 A prospective randomized, double-blind phase 2 study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: Compared with 68Ga-DOTATATE

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Jia R, Cheng Y, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, 68Ga-DOTATATE, neuroendocrine tumor,

#3332 A prospective randomized, double-blind study to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors

Introduction: 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 specific antagonists used for PET/CT imaging.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Zhu W, Cheng Y, Jia R, Zhao H, Bai C,

Keywords: somatostatin receptor antagonist, 68Ga-NODAGA-LM3, 68Ga-DOTA-LM3, neuroendocrine tumor,